Summary

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center
(MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose
of this study is to collect normal and cancerous tissues, in addition to blood, and other
body fluid samples from men with prostate cancer or prostatic disease. These samples may be
stored for future use or used immediately by researchers who study prostate cancer and try
to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and
protein markers on these cells. We hope to learn more about what makes some people get
prostate cancer, why some cancers are more aggressive than others, and why some cancers
respond to or resist different treatments. We may also try to grow the tumor cells in the
lab. We may find a new treatment for prostate cancer based on this research.

Additional Information

The therapeutics program for advanced prostate cancer is based on the hypothesis that the
factors contributing to and associated with progression change as the disease evolves. To
categorize these changes we now consider the disease as a series of states. 1 The states
represent points where an intervention might be considered to prevent cancer from
developing, to eliminate established disease, or to delay progression. The states also
represent clinically significant milestones that can be used to assess treatment effects.

Trial information was received from ClinicalTrials.gov and was last updated in August 2016.